Retatrutide (development code LY3437943) is an investigational synthetic peptide developed by Eli Lilly and Company. It is classified as a triple receptor agonist.
Molecular Targets
Retatrutide simultaneously activates three G-protein-coupled receptors:
- Glucose-dependent insulinotropic polypeptide (GIP) receptor
- Glucagon-like peptide-1 (GLP-1) receptor
- Glucagon receptor
This multi-receptor profile distinguishes it from selective GLP-1 receptor agonists (such as semaglutide) and dual GIP/GLP-1 agonists (such as tirzepatide).
Structure and Properties
Retatrutide is a single-chain peptide conjugated to a fatty diacid moiety. This modification extends its pharmacokinetic profile, resulting in a half-life of approximately six days, which supports once-weekly subcutaneous administration in clinical studies.
Relative potency compared with the endogenous ligands varies by receptor: it shows higher potency at the GIP receptor and comparatively lower potency at the GLP-1 and glucagon receptors.
Research Context
Retatrutide is currently under evaluation in the TRIUMPH Phase 3 clinical trial program. It remains an investigational compound and has not received regulatory approval for any indication.
This summary is limited to the molecule’s identity, receptor pharmacology, and development status.